Early Detection Research Network

CA15-3

Aliases:
This biomarker is also known as:
  • MUC-1/X,
  • Krebs Von Den Lungen-6,
  • MUC1/ZD,
  • PEMT,
  • ADMCKD1,
  • Polymorphic Epithelial Mucin,
  • MCKD1,
  • MUC1,
  • CA 15-3,
  • MCKD,
  • Mucin 1, Cell Surface Associated,
  • Tumor Associated Epithelial Mucin,
  • CA15-3,
  • Mucin-1,
  • CD227,
  • Episialin,
  • KL-6,
  • PEM,
  • Cancer Antigen 15-3,
  • H23 Antigen,
  • Mucin 1, Transmembrane,
  • Medullary Cystic Kidney Disease, Autosomal Dominant,
  • Medullary Cystic Kidney Disease 1 (Autosomal Dominant),
  • DF3 Antigen,
  • Tumor-Associated Mucin,
  • MAM6,
  • MUC-1,
  • CD227 Antigen,
  • Carcinoma-Associated Mucin,
  • Breast Carcinoma-Associated Antigen DF3,
  • MCD,
  • Tumor-Associated Epithelial Membrane Antigen,
  • MUC-1/SEC,
  • PUM,
  • CA15.3,
  • Peanut-Reactive Urinary Mucin,
  • ADMCKD,
  • EMA,
  • H23AG,

Description…

From NCBI Gene: This gene encodes a membrane-bound protein that is a member of the mucin family. Mucins are O-glycosylated proteins that play an essential role in forming protective mucous barriers on epithelial surfaces. These proteins also play a role in intracellular signaling. This protein is expressed on the apical surface of epithelial cells that line the mucosal surfaces of many different tissues including lung, breast stomach and pancreas. This protein is proteolytically cleaved into alpha and beta subunits that form a heterodimeric complex. The N-terminal alpha subunit functions in cell-adhesion and the C-terminal beta subunit is involved in cell signaling. Overexpression, aberrant intracellular localization, and changes in glycosylation of this protein have been associated with carcinomas. This gene is known to contain a highly polymorphic variable number tandem repeats (VNTR) domain. Alternate splicing results in multiple transcript variants.[provided by RefSeq, Feb 2011]

Datasets

There are no datasets associated with this biomarker.

Attributes
QA State: Accepted
Type: Protein
HGNC Name: MUC1

The following organs have data associated with this biomarker…

Attributes

Phase: One
QA State: Curated

Overview

No additional data available.

Performance Comment

Ninety biomarkers were measured using a series of multiplexed immunoassays and results analyzed by the EDRN data management center splitting the cases and controls into training and validation sets, excluding subjects with DCIS or atypical hyperplasia from the training phase. We found little evidence that any of these markers can discriminate women with invasive cancer from those with benign breast conditions.

Supporting Study Data

The following studies/protocols provide evidence supporting CA15-3 indications for the Breast…

No supporting studies or protocols found.

Organ-Specific Protocols

No organ-specific protocols defined.

Organ-Specific Publications

No organ-specific publications defined.

Organ-Specific Resources

No organ-specific resources defined.

Attributes

Phase: Two
QA State: Under Review

Overview

Performance Comment

Supporting Study Data

The following studies/protocols provide evidence supporting CA15-3 indications for the Lung…

No supporting studies or protocols found.

Organ-Specific Protocols

No organ-specific protocols defined.

Organ-Specific Publications

No organ-specific publications defined.

Organ-Specific Resources

No organ-specific resources defined.

Attributes

Phase: Three
QA State: Accepted

Overview

CA15-3 may be a molecular marker for ovarian cancer. Literature suggests that the concomitant measurement of CA15-3 with CA125 could be advantageous in the pre-operative discrimination of benign and malignant ovarian tumors.

Performance Comment

Of the 28 ovarian cancer biomarkers tested in prediagnostic specimens, from the PLCO, CA125 remains the the single best biomarker for ovarian cancer and has its strongest signal within six months of diagnosis. CA15-3 alone was not a strong predictor.

Supporting Study Data

The following studies/protocols provide evidence supporting CA15-3 indications for the Ovary…

No supporting studies or protocols found.

Organ-Specific Protocols

No organ-specific protocols defined.

Organ-Specific Publications

No organ-specific publications defined.

Organ-Specific Resources

No organ-specific resources defined.

Attributes

Phase: One
QA State: Under Review

Overview

No additional data available.

Performance Comment

The Canary TMA prostate biomarkers are still under investigation.

Supporting Study Data

The following studies/protocols provide evidence supporting CA15-3 indications for the Prostate…

No supporting studies or protocols found.

Organ-Specific Protocols

No organ-specific protocols defined.

Organ-Specific Publications

No organ-specific publications defined.

Organ-Specific Resources

No organ-specific resources defined.

No associated publications found.